EDTA Chelation Therapy

Dr. Steensma Discusses Iron Chelation Therapy for MDS

Dr. Steensma Discusses Iron Chelation Therapy For MDS

David P. Steensma, MD, attending physician, hematologic oncology, Dana-Farber Cancer Institute, Boston, MA, discusses the arguments against the use of iron chelation in patients with myelodysplastic syndrome (MDS).

Dr. Steensma Discusses Iron Chelation Therapy For MDS

One of the reasons some hematologic oncologists do not use chelation is because the 2 largest prospective studies that investigated it in MDS patients experienced dropout rates close to 50%. This high of a dropout rate is unusual, and was related to adverse events, disease progression, and unrelated deaths.

Dr. Steensma Discusses Iron Chelation Therapy For MDS

Steensma notes that despite the avid promotion of using iron chelation for MDS patients there is currently no prospective data showing morbidity or mortality benefits. An ongoing prospective trial, labeled TELESTO, plans to investigate the event free survival of MDS patients when treated with iron chelation; however, due to the strong opinions of physicians the trial has had a difficult time recruiting participants. Some retrospective studies support the use of iron chelation but Steensma explains that retrospective studies are inherently biased because the cause of a decision may have been due to an unrelated factor.

Dr. Steensma Discusses Iron Chelation Therapy For MDS

There is generally a low occurrence of side effects to chelation treatment when it is given correctly. The most common adverse events are diarrhea and an upset stomach, or more seriously, kidney failure. The overall safety and efficacy of iron chelation for patients with MDS remains greatly unknown. Without further prospective data it is difficult to address the concerns regarding the true risk and benefit balance of this treatment.

Dr. Steensma Discusses Iron Chelation Therapy For MDS

Dr. Steensma Discusses Iron Chelation Therapy for MDS

David P. Steensma, MD, attending physician, hematologic oncology, Dana-Farber Cancer Institute, Boston, MA, discusses the arguments against the use of iron chelation in patients with myelodysplastic syndrome (MDS).

One of the reasons some hematologic oncologists do not use chelation is because the 2 largest prospective studies that investigated it in MDS patients experienced dropout rates close to 50%. This high of a dropout rate is unusual, and was related to adverse events, disease progression, and unrelated deaths.

Steensma notes that despite the avid promotion of using iron chelation for MDS patients there is currently no prospective data showing morbidity or mortality benefits. An ongoing prospective trial, labeled TELESTO, plans to investigate the event free survival of MDS patients when treated with iron chelation; however, due to the strong opinions of physicians the trial has had a difficult time recruiting participants. Some retrospective studies support the use of iron chelation but Steensma explains that retrospective studies are inherently biased because the cause of a decision may have been due to an unrelated factor.

There is generally a low occurrence of side effects to chelation treatment when it is given correctly. The most common adverse events are diarrhea and an upset stomach, or more seriously, kidney failure. The overall safety and efficacy of iron chelation for patients with MDS remains greatly unknown. Without further prospective data it is difficult to address the concerns regarding the true risk and benefit balance of this treatment.

Dr. Steensma Discusses Iron Chelation Therapy For MDS
Dr. Steensma Discusses Iron Chelation Therapy For MDS
Dr. Steensma Discusses Iron Chelation Therapy For MDS

One Comment

  1. Our experience in India since 1994 with chelation therapy for ischemic
    heart disease, cerebral ischemia and peripheral artery disease has been
    excellent. My and my wife’s training in MBBS and MD caused our first
    reaction about Chelation Therapy in 1992-1993 to be a biased negative. One
    of the reasons that initiated and ”forced” in to practice Chelation
    therapy was when someone close to me had a coronary artery stent failure
    within just a couple of months. He wanted me to explore other options as he
    could not afford bypass surgery. At the same time a close doctor friend
    onf mine approached me to study Chelatiopn therapy for his mother’s angina.
    We took training and did the Chelation therapy not expecting any benefit –
    but the patient made a marvellous recovery. One patient led to another –
    all improved. It took us three years to finally come to terms with our
    mental block and ultimately accept Chelation Therapy as an effective, safe
    and economical treatment. With the experience of Chelation we ventured into
    other non-invasive, non-surgical treatments for other ailments.
    Non-surgical treatments have a special place not only the developing
    countries but also the developed ones. We do wish that there is more
    research on Chelation and various other such treatments and invite
    like-minded medical and non medical persons to support our efforts. Anyone
    wanting more information is welcome to contact us or visit educational
    website http://www.chelation.in or call helpline Ph / Cell / Mb: +91-9814034818 –
    Dr Sibia

Comments are closed.

Ancient All-Natural Chinese Secrets Shrink Prostate FAST!

" Discover How These Chinese Herbs Solved My Sexual & Prostate Problems Without Flomax, Viagra Or Any Other Drugs Within 14 Days! "

Stroke Management. Self-Care ( Part 1)

Click Here To Learn More!